Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who completed the 12-month core study (NCT00061750)
Female patients after menarche and who were sexually active, if they used double-barrier contraception, oral contraceptive plus barrier contraceptive, or had undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation
Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation
You may not be if
Pregnant or breast feeding patients
Patients with a history of non-compliance to medical regimens or those considered to be potentially unreliable
Clareo Health | An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
